

# Alejandro Forner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6709136/publications.pdf>

Version: 2024-02-01

123  
papers

41,092  
citations

71061

41  
h-index

16636

123  
g-index

148  
all docs

148  
docs citations

148  
times ranked

29569  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sorafenib in Advanced Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2008, 359, 378-390.	13.9	12,004
2	EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018, 69, 182-236.	1.8	6,153
3	Hepatocellular carcinoma. <i>Lancet, The</i> , 2012, 379, 1245-1255.	6.3	3,897
4	Hepatocellular carcinoma. <i>Lancet, The</i> , 2018, 391, 1301-1314.	6.3	3,878
5	Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. <i>Lancet Oncology, The</i> , 2009, 10, 35-43.	5.1	1,920
6	BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. <i>Journal of Hepatology</i> , 2022, 76, 681-693.	1.8	1,495
7	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 557-588.	8.2	1,155
8	Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects. <i>Seminars in Liver Disease</i> , 2010, 30, 061-074.	1.8	945
9	Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. <i>Hepatology</i> , 2008, 47, 97-104.	3.6	884
10	Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. <i>Lancet Oncology, The</i> , 2012, 13, e11-e22.	5.1	872
11	Chemoembolization of hepatocellular carcinoma with drug eluting beads: Efficacy and doxorubicin pharmacokinetics. <i>Journal of Hepatology</i> , 2007, 46, 474-481.	1.8	864
12	Management of HCC. <i>Journal of Hepatology</i> , 2012, 56, S75-S87.	1.8	509
13	Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization. <i>Cancer Treatment Reviews</i> , 2011, 37, 212-220.	3.4	460
14	Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. <i>Journal of Hepatology</i> , 2012, 56, 1330-1335.	1.8	436
15	Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma. <i>Cancer</i> , 2009, 115, 616-623.	2.0	403
16	Treatment of intermediate-stage hepatocellular carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 525-535.	12.5	377
17	Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. <i>Cancer Treatment Reviews</i> , 2019, 72, 28-36.	3.4	342
18	Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. <i>Hepatology</i> , 2010, 51, 2020-2029.	3.6	268

#	ARTICLE	IF	CITATIONS
19	Cholangiocarcinoma in cirrhosis: Absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. <i>Hepatology</i> , 2009, 50, 791-798.	3.6	253
20	COVID-19 and liver disease. <i>Liver International</i> , 2020, 40, 1278-1281.	1.9	252
21	Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and Therapy. <i>Annual Review of Medicine</i> , 2010, 61, 317-328.	5.0	229
22	Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial design. <i>Hepatology</i> , 2013, 58, 2023-2031.	3.6	217
23	Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. <i>Journal of Hepatology</i> , 2014, 61, 318-324.	1.8	203
24	A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. <i>BMC Cancer</i> , 2010, 10, 209.	1.1	174
25	Clinical presentation, diagnosis and staging of cholangiocarcinoma. <i>Liver International</i> , 2019, 39, 98-107.	1.9	171
26	Non-invasive diagnosis of hepatocellular carcinoma $\leq 2$ cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI. <i>Journal of Hepatology</i> , 2012, 56, 1317-1323.	1.8	159
27	Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and Tj ETQq1 1 0.784314 rgBT /Overlock). <i>Journal of Hepatology</i> , 2014, 61, 1481-1487.	6.1	154
28	New aspects of diagnosis and therapy of hepatocellular carcinoma. <i>Oncogene</i> , 2006, 25, 3848-3856.	2.6	143
29	Treatment of hepatocellular carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 60, 89-98.	2.0	140
30	Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. <i>Journal of Hepatology</i> , 2022, 76, 1109-1121.	1.8	119
31	Liver Imaging Reporting and Data System with MR Imaging: Evaluation in Nodules 20 mm or Smaller Detected in Cirrhosis at Screening US. <i>Radiology</i> , 2015, 275, 698-707.	3.6	115
32	Systemic Therapy for Hepatocellular Carcinoma: The Issue of Treatment Stage Migration and Registration of Progression Using the BCLC-Refined RECIST. <i>Seminars in Liver Disease</i> , 2014, 34, 444-455.	1.8	112
33	Biomarkers for early diagnosis of hepatocellular carcinoma. <i>Lancet Oncology</i> , The, 2012, 13, 750-751.	5.1	102
34	Clinical decision making and research in hepatocellular carcinoma: Pivotal role of imaging techniques. <i>Hepatology</i> , 2011, 54, 2238-2244.	3.6	101
35	Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection. <i>Hepatology</i> , 2016, 63, 839-849.	3.6	101
36	Chemoembolization for intermediate HCC: Is there proof of survival benefit?. <i>Journal of Hepatology</i> , 2012, 56, 984-986.	1.8	99

#	ARTICLE	IF	CITATIONS
37	Î±-Fetoprotein for Hepatocellular Carcinoma Diagnosis: The Demise of a Brilliant Star. <i>Gastroenterology</i> , 2009, 137, 26-29.	0.6	89
38	Prognostic Prediction in Patients with Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 2005, 25, 171-180.	1.8	80
39	Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.. , 2021, 9, e003311.		66
40	Lack of arterial hypervascularity at contrast-enhanced ultrasound should not define the priority for diagnostic work-up of nodules &lt;2cm. <i>Journal of Hepatology</i> , 2015, 62, 150-155.	1.8	46
41	Controversies in the management of hepatocellular carcinoma. <i>JHEP Reports</i> , 2019, 1, 17-29.	2.6	45
42	Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 482-491.	1.9	40
43	Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System. <i>Hepatology</i> , 2021, 73, 2311-2325.	3.6	40
44	Consensus Report of the Fifth International Forum for Liver MRI. <i>American Journal of Roentgenology</i> , 2013, 201, 97-107.	1.0	38
45	Assessing the impact of COVID-19 on liver cancer management (CERO-19). <i>JHEP Reports</i> , 2021, 3, 100260.	2.6	36
46	CT/MRI and CEUS LI-RADS Major Features Association with Hepatocellular Carcinoma: Individual Patient Data Meta-Analysis. <i>Radiology</i> , 2022, 302, 326-335.	3.6	32
47	Treatment of early hepatocellular carcinoma: Towards personalized therapy. <i>Digestive and Liver Disease</i> , 2010, 42, S242-S248.	0.4	31
48	Hepatocellular carcinoma surveillance with miRNAs. <i>Lancet Oncology</i> , The, 2015, 16, 743-745.	5.1	31
49	Hepatocellular carcinoma " Authors' reply. <i>Lancet</i> , The, 2012, 380, 470-471.	6.3	29
50	Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma. <i>Hepatology</i> , 2016, 63, 488-498.	3.6	27
51	Surveillance for hepatocellular carcinoma. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2016, 30, 1001-1010.	1.0	25
52	Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma. <i>European Radiology</i> , 2020, 30, 186-194.	2.3	25
53	Thermal Ablation for Intrahepatic Cholangiocarcinoma in Cirrhosis: Safety and Efficacy in Non-Surgical Patients. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 710-719.	0.2	25
54	New drugs for the treatment of hepatocellular carcinoma. <i>Liver International</i> , 2009, 29, 148-158.	1.9	22

#	ARTICLE	IF	CITATIONS
55	Prognosis prediction and staging. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 855-865.	1.0	20
56	Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 10-10.	12.5	20
57	Prospective evaluation of gadoxetic acid magnetic resonance for the diagnosis of hepatocellular carcinoma in newly detected nodules in cirrhosis. <i>Liver International</i> , 2019, 39, 1281-1291.	1.9	20
58	Metabolic risk factors are a major comorbidity in patients with cirrhosis independent of the presence of hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 1239-1244.	0.8	18
59	Locoregional treatment for hepatocellular carcinoma: From clinical exploration to robust clinical data, changing standards of care. <i>Hepatology</i> , 2007, 47, 5-7.	3.6	17
60	Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules. <i>Journal of Hepatology</i> , 2022, 76, 874-882.	1.8	17
61	Ileal carcinoid tumor as a cause of massive lower-GI bleeding: the role of capsule endoscopy. <i>Gastrointestinal Endoscopy</i> , 2004, 60, 483-485.	0.5	16
62	Ablation for hepatocellular carcinoma: Is there need to have a winning technique?. <i>Journal of Hepatology</i> , 2010, 52, 310-312.	1.8	16
63	What is the best staging system for hepatocellular carcinoma in the setting of liver transplantation?. <i>Liver Transplantation</i> , 2011, 17, S26-S33.	1.3	16
64	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. <i>Medicina Clínica (English Edition)</i> , 2021, 156, 463.e1-463.e30.	0.1	16
65	East meets the West—portal pressure predicts outcome of surgical resection for hepatocellular carcinoma. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2009, 6, 14-15.	1.7	15
66	Impact of Reference Standard on CT, MRI, and Contrast-enhanced US LI-RADS Diagnosis of Hepatocellular Carcinoma: A Meta-Analysis. <i>Radiology</i> , 2022, 303, 544-545.	3.6	15
67	Transarterial chemoembolization for patients with hepatocellular carcinoma. <i>Hepatology Research</i> , 2007, 37, S230-7.	1.8	14
68	Hepatic epithelioid hemangioendothelioma: An international multicenter study. <i>Digestive and Liver Disease</i> , 2020, 52, 1041-1046.	0.4	13
69	Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. <i>Saudi Journal of Gastroenterology</i> , 2020, 26, 1.	0.5	13
70	New challenges in clinical research on hepatocellular carcinoma. <i>Revista Espanola De Enfermedades Digestivas</i> , 2015, 108, 485-93.	0.1	12
71	Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions by 2025. <i>Journal of Hepatology</i> , 2020, 73, 1360-1367.	1.8	12
72	Sunitinib and the benefits of a negative study. <i>Lancet Oncology</i> , The, 2009, 10, 743-744.	5.1	11

#	ARTICLE	IF	CITATIONS
73	IFN-free therapy for HIV/HCV-coinfected patients within the liver transplant setting. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3195-3201.	1.3	11
74	Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions. <i>Gut</i> , 2022, , gutjnl-2022-327099.	6.1	11
75	Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study. <i>Liver International</i> , 2022, 42, 1891-1901.	1.9	11
76	Impact of Positive Lymph Nodes and Resection Margin Status on the Overall Survival of Patients with Resected Perihilar Cholangiocarcinoma: The ENSCCA Registry. <i>Cancers</i> , 2022, 14, 2389.	1.7	10
77	Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival. <i>Journal of Hepatology</i> , 2021, 75, 1154-1163.	1.8	9
78	Reply:. <i>Hepatology</i> , 2008, 47, 2146-2147.	3.6	8
79	Does transient arterial-phase respiratory-motion-related artifact impact on diagnostic performance? An intra-patient comparison of extracellular gadolinium versus gadoxetic acid. <i>European Radiology</i> , 2020, 30, 6694-6701.	2.3	8
80	Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules $\geq 2$ cm in cirrhotic patients. <i>European Radiology</i> , 2021, 31, 4794-4803.	2.3	8
81	Barcelona Clinic Liver Cancer 2022 update: Linking prognosis prediction and evidence-based treatment recommendation with multidisciplinary clinical decision-making. <i>Liver International</i> , 2022, 42, 488-491.	1.9	8
82	Intermediate-stage HCC"upfront resection can be feasible. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 295-295.	12.5	7
83	Transarterial therapies in HCC: Does embolization increase survival?. <i>Journal of Hepatology</i> , 2009, 51, 981-983.	1.8	6
84	Approach of the patient with a liver mass. <i>Frontline Gastroenterology</i> , 2012, 3, 252-262.	0.9	6
85	Natural history and staging for hepatocellular carcinoma. <i>Clinical Liver Disease</i> , 2012, 1, 183-185.	1.0	6
86	Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials. <i>Liver International</i> , 2020, 40, 2476-2488.	1.9	6
87	Diagnosis and staging of hepatocellular carcinoma prior to transplantation: Expertise or failure. <i>Liver Transplantation</i> , 2006, 12, 1445-1447.	1.3	5
88	Non-invasive diagnostic criteria for hepatocellular carcinoma: The value of contrast washout at imaging and the death of alpha-fetoprotein. <i>Liver International</i> , 2011, 31, 1419-1421.	1.9	5
89	The Size of the Problem: Clinical Algorithms. <i>Digestive Diseases</i> , 2013, 31, 95-103.	0.8	5
90	Is downstaging a reliable strategy for expanding criteria for liver transplantation in hepatocellular carcinoma?. <i>Lancet Oncology</i> , The, 2020, 21, 867-869.	5.1	4

#	ARTICLE	IF	CITATIONS
91	Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 426.	1.7	4
92	Editorial: aspirin and NSAID for chemoprevention of hepatocellular carcinomaâ€”ready for their use?. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 850-851.	1.9	4
93	Clinical research in hepatocellular carcinoma: Study design and endpoints. <i>Journal of Hepatology</i> , 2009, 50, 850-853.	1.8	3
94	To Expand or Not to Expand the Criteria for Hepatocellular Carcinoma Transplantation: Is Downstaging the Answer?. <i>Gastroenterology</i> , 2009, 137, 375-376.	0.6	3
95	Does ramucirumab deserve a second chance for liver cancer?. <i>Lancet Oncology</i> , The, 2015, 16, 751-752.	5.1	3
96	Human immunodeficiency virusâ€”infected liver transplant recipients with incidental hepatocellular carcinoma: A prospective multicenter nationwide cohort study. <i>Liver Transplantation</i> , 2017, 23, 645-651.	1.3	3
97	Intention-to-treat curative liver resection in patients with â€œvery earlyâ€”intrahepatic cholangiocarcinoma. <i>Langenbeck's Archives of Surgery</i> , 2020, 405, 967-975.	0.8	3
98	The tireless search to improve the prognostic assessment of intrahepatic cholangiocarcinoma: An urgent need. <i>Liver International</i> , 2021, 41, 252-254.	1.9	3
99	Hepatocellular adenoma in men: Is it time for a precision approach?. <i>Liver International</i> , 2021, 41, 2246-2248.	1.9	3
100	Pancreatic Insufficiency in Patients Under Sorafenib Treatment for Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2021, 55, 263-270.	1.1	3
101	Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. <i>Medicina Clnica (English Edition)</i> , 2016, 146, 511.e1-511.e22.	0.1	2
102	Conclusive HCC diagnosis with hepatocyte-specific contrast-enhanced magnetic resonance imaging? Not yet. <i>Journal of Hepatology</i> , 2016, 65, 648-649.	1.8	2
103	PS-115-Evaluation of LI-RADS v2018 by magnetic resonance in US-detected nodules < 2 cm in cirrhotics. <i>Journal of Hepatology</i> , 2019, 70, e73.	1.8	2
104	Systemic doxorubicin and hepatocellular carcinoma: the end of an era never risen up. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 418-420.	3.7	2
105	Adherence and quality are key for a beneficial HCC surveillance. <i>Liver International</i> , 2020, 40, 751-753.	1.9	2
106	EarlyÂdiarrhoea under sorafenib as a marker to consider the early migration to secondâ€”line drugs. <i>United European Gastroenterology Journal</i> , 2021, 9, 655-661.	1.6	2
107	REPLY:. <i>Hepatology</i> , 2021, 74, 1129-1131.	3.6	2
108	The Maze of Systemic Therapy for Hepatocellular Carcinoma: Did We Find the Compass?. <i>Gastroenterology</i> , 2022, 162, 1770-1772.	0.6	2

#	ARTICLE	IF	CITATIONS
109	Mutational profile of skin lesions in hepatocellular carcinoma patients under tyrosine kinase inhibition: a repercussion of a wide-spectrum activity. <i>Oncotarget</i> , 2021, 12, 440-449.	0.8	1
110	REPLY:. <i>Hepatology</i> , 2021, 74, 2319-2321.	3.6	1
111	Reply:. <i>Hepatology</i> , 2009, 50, 1316-1317.	3.6	0
112	Reply:. <i>Hepatology</i> , 2010, 52, 1516-1517.	3.6	0
113	Evoluci3n natural y estratificaci3n del carcinoma hepatocelular. <i>Clinical Liver Disease</i> , 2013, 2, S333-S363.	1.0	0
114	Liver Transplantation for Hepatocellular Carcinoma in HCV-Infected Patients. , 2014, , 77-93.		0
115	Reply to: "Poor contrast enhanced ultrasonography! There is no limit to its decline in the diagnosis of hepatocellular carcinoma on cirrhosis!" <sup>TM</sup> . <i>Journal of Hepatology</i> , 2015, 62, 1453-1454.	1.8	0
116	Carbon13 ion radiotherapy for HCC: A potential tool to fulfil an unmet gap in the treatment algorithms?. <i>Liver International</i> , 2018, 38, 2132-2133.	1.9	0
117	Prognosis assessment by pathologist: Is the detection of intratumoural tertiary lymphoid structures a reliable tool?. <i>Journal of Hepatology</i> , 2019, 70, 11-12.	1.8	0
118	Una causa infrecuente de s3ndrome inflamatorio sist3mico. <i>Gastroenterolog3a Y Hepatolog3a</i> , 2019, 42, 383-384.	0.2	0
119	Increasing alternatives in systemic treatment for hepatocellular carcinoma: Will algorithms be understandable?. <i>Liver International</i> , 2020, 40, 1829-1831.	1.9	0
120	Hepatobiliary contrast agents in MR: Where we stand and future perspectives. <i>Liver International</i> , 2021, 41, 888-890.	1.9	0
121	The complexity of cholangiocarcinoma goes beyond clinical practice: Challenges in trials design and interpretation. <i>Liver International</i> , 2022, 42, 268-270.	1.9	0
122	Portal hypertension may influence the registration of hypointensity of small hepatocellular carcinoma in the hepatobiliary phase in gadoteric acid MR. <i>Radiology and Oncology</i> , 2022, 56, 292-302.	0.6	0
123	Low Baseline Plasma L-Glutamine Concentration Identifies Hepatocellular Carcinoma Patients at High Risk of Developing Early Gastrointestinal Adverse Events during Sorafenib Treatment. <i>Gastrointestinal Disorders</i> , 2022, 4, 141-152.	0.4	0